Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**62Cu-NOTA-GGG-Re(Arg11)CCMSH** is a radiolabeled peptide-based imaging agent designed for the selective targeting and positron emission tomography (PET) imaging of melanoma. It utilizes the bifunctional chelator NOTA to anchor the radionuclide copper-62 (62Cu), with a GGG spacer and a cyclized melanotropin analogue (Re(Arg11)CCMSH) that is engineered for high-affinity binding to the melanocortin-1 receptor (MC1-R), overexpressed in melanoma cells. The drug is prepared in a rapid one-step synthesis, exhibits high specific activity, and demonstrates selective and rapid tumor uptake in preclinical models. This compound specifically enables visualization of melanoma tumors in vivo using PET, supporting both diagnostic and potential therapeutic applications based on radiolabeled peptide performance[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 62Cu-NOTA-GGG-Re(Arg11)CCMSH.